Kline: 2.1B adults in 25 countries eat “GLP‑1 style”; 89M use the drugs
Kline and Company estimates 2.1 billion adults across 25 countries follow GLP-1-aligned eating patterns, while about 89 million people use the drugs. The gap is widest outside North America. Food makers chasing that demand reach more shoppers by leading with protein, fiber and portion size than with GLP-1 labels.
This story was produced through MarketScale. See how Food & Beverage teams put it to work with Customer Stories & Case Studies.
Key takeaways
A product designed only for people on the injection targets the smallest slice of shoppers: a rough calculation suggests ~24 halo consumers per GLP‑1 user, though the counts aren’t like-for-like.
Where prescriptions are scarce, the halo-first case is strongest: Europe, Latin America and Asia Pacific have proportionally larger halos because far fewer people there take the drugs.
The next segment to plan for is people coming off the drugs: Kline expects one in three ever-users to be recent stoppers by 2035, and their baskets keep some habits and drop others.
Free workspace
Turn your Food & Beverage expertise into content.
Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.
Eighty-nine million people around the world take a GLP-1 drug. Kline and Company thinks 2.1 billion are eating as if they did.
Augustus Bambridge-Sutton reported the estimate in FoodNavigator on November 13. Kline calls the larger group the GLP-1 halo: adults who don't use the drugs but follow GLP-1-aligned eating patterns. Elizabeth Thundow, Kline's vice president for food and nutrition, describes them as people with a strong concern about metabolic health. The 2.1 billion figure works out to 56% of adults in the 25 countries Kline assessed.
For an R&D director deciding what a new bar, yoghurt or frozen meal should say on its front panel, the ratio matters more than either number. Simple division gives roughly 24 halo consumers for every user. That's only a rough figure, because the user count is global and the halo covers 25 countries. Even so, the direction is clear. A product designed only for people on the injection is designed for the smallest slice of the people now shopping like them.
Kline's GLP-1 demand math
Kline and Company, via FoodNavigator
A halo that grows as prescriptions thin out
The gap between users and halo shifts a lot by region. North America has the proportionally smallest halo, and Kline says that's because it has the largest user base. Europe, Latin America and Asia Pacific have proportionally larger halos because far fewer people there take the drugs, and the report's overview names Asia Pacific as the region that dominates the halo. In Europe, FoodNavigator notes, uptake lags partly because medical systems differ and partly because consumers are sceptical. Africa and the Middle East were not assessed.
That changes how an export-minded portfolio team should read prescription data. For brands selling into Europe or Asia Pacific, drug adoption curves are a poor proxy for demand, because most of the people shopping GLP-1 style there got to that diet without a prescription.
Separate consumer data points the same way. In a guest column for Food Industry Executive, Fi Events brand director Yannick Verry cites Innova Market Insights figures on how consumers who acted on weight concerns went about it. Exercise and eating less far outrank medication. Innova also tracked a 14% rise in weight management claims worldwide in a single year, from 2024 to 2025.
The motive behind the halo is showing up in other research too. At the supplement trends session of SupplySide Global, Nutrition Business Journal's Bill Giebler and Erika Craft reported that more than one-third of consumers surveyed are engaging with metabolic health, which Craft defined as how the body processes energy. Understanding falls with age: the consumers most likely to be unsure what the term meant were over 60. The surveys differ from Kline's, but they describe the same concern Thundow uses to define the halo, which suggests it is a mainstream motive rather than a niche one.
The strongest objection to the halo-first reading comes from the US, where the user segment is large and growing quickly. Food Processing's Andy Hanacek cited a Hartman Group white paper showing 12.4% of US consumers on GLP-1 drugs, up from 5.8% in 2024. Circana's measure, taken by household rather than by person, puts 23% of US households as having a user. Its research, reported by Food Engineering in November 2025, projects those households will account for 35% of all US food and beverage units sold by 2030. Among users, weight management as a primary health goal is up 41 points since 2021.
Ardent Mills' Matt Schueller told Food Processing he expects another wave of adopters as pill formats arrive, prices fall and employers start covering the drugs. Hormel Foods' Jason Baskin said GLP-1s are "just scratching the surface of where they're going to be even five years from now." The pill route has clinical data behind it. A January 2026 review in the International Journal of Molecular Sciences reports that orforglipron, an oral small-molecule GLP-1 drug designed to improve convenience and adherence over injectables, produced significant reductions in body weight and HbA1c in Phase 1 to 3 trials.
In North America, then, medicated users are a market worth designing for directly. Circana's projection, if it holds, would send roughly a third of US units through user households by the end of the decade. The halo-first case is strongest where prescriptions are scarce.
Yoghurt gains, snacks and cereal give ground
Kline says that $10bn in US food spending is already moving toward yoghurts, meat snacks, nutrition bars and fresh fruit. More broadly, it expects lifestyle nutrition and dairy to benefit, while snacks, bakery and breakfast cereals may lose out.
Household-level data shows how sharp the early hit can be. The Hartman Group, as reported by Food Processing, cites a December 2025 Journal of Marketing Research study. Six months after someone in the household started a GLP-1 drug, households spent 5.3% less on groceries, 10.1% less on savory snacks and 8% less at quick-service restaurants. Savory snacks took the deepest cut, which fits Kline's list of categories at risk.
Circana's report adds a wrinkle. Users' spending on traditional retail food and beverages has fallen while their restaurant spending has risen, and in the store they are buying more products high in protein, fiber and healthy fats and fewer high in carbohydrates and sugar. Even after cutting back, they still outspend non-users at retail.
The restaurant finding doesn't contradict the journal study, whose quick-service category covered only fast-food chains, coffee shops and limited-service restaurants. And a household that buys less but still outspends non-users suggests the user basket is smaller in volume yet still worth more than the average non-user's.
Then the curve flattens. Capital One's food, beverage and agriculture banking group found that users cut calories most in their first six months, cut a little more by month 12, and then hold steady. In its research, food volume stabilizes after the first year and then rises about 1%.
Paul Baisley, who heads that group, argues GLP-1s have become an easy target for blame when numerous other economic factors are pushing food volumes down. The bank's report also estimates users could gain 14 years of life expectancy. Colin Guheen, a managing director in its investment research group, connected the two: a calorie hit "largely contained to the first 12 months" combined with people living longer makes users "longer-term" consumers of food products.
This suggests demand planners are dealing with two separate effects. Users eat less because the drug suppresses appetite, and that hit mostly lands in year one. Halo consumers aren't on an appetite suppressant. They're changing what goes in the cart. A forecast that treats both groups as one GLP-1 effect will overstate volume loss in the halo and understate how much the product mix is shifting.
Lead with protein, not the prescription
The packaging question came up at SupplySide Global in Las Vegas, where a GLP-1 session drew the most preregistrations of any long-form education program, according to SupplySide Food & Beverage Journal. NielsenIQ's Sherry Frey told attendees that non-users want much of what users want but won't necessarily be drawn to products marketed to people on the drugs. Her advice was to lead with higher protein and fiber callouts to reach the wider audience.
Verry makes the same point from the brand side. He says mid-market brands face the most pressure and should lead with high protein, fiber and portion size rather than naming GLP-1s. Smaller portions and higher expectations for fullness, he argues, put more weight on protein, fiber and micronutrient density per serving. That pushes formats toward single-serve packs and mini meals.
The specification work is getting more specific too. Frey's data set the bar: food now has to deliver more nutrition in fewer bites while still offering a strong sensory experience, particularly variation in texture. David Despain of Nestlé Health Science told the same audience that products need the highest possible nutrient density per calorie, with protein and fiber at every eating occasion. He added that fiber should be spread across the day to avoid digestive distress.
Allyn Kaufmann of Haleon urged developers to use ingredients that have been studied in GLP-1 populations and warned against marketing that gets ahead of the science. Dole's Melanie Marcus, speaking to Food Processing, named fiber and hydration as two of the biggest nutritional gaps for users. Dole's GLP-1 resources page is built around exactly those problems: low fiber intake, poor hydration and the risk of losing weight too quickly.
Heidi Skolnik, a dietitian and spokesperson for Link Snacks, explains why each serving now carries more weight. "Nutrient density matters because appetites are lower and cravings are different," she told Food Processing, adding that there is "less room now, with fewer discretionary calories." For some users, she says, snacks may replace meals outright, which turns snack composition into a meal-planning question. Protein has an extra job as well: a patient explainer from telehealth provider Halo-RX Meds notes that part of the weight lost on GLP-1s is lean mass, so protein intake matters.
Before approving a front-panel claim, ask whether the product would still sell to someone who has never taken the drug. If the pitch depends on the word GLP-1, it is speaking to the smaller market.
People coming off the drugs
Kline's forecast adds a third group. In most countries it assessed, people who have ever used a GLP-1 already outnumber current users. By 2035 Kline expects user numbers to double, and it expects one in three people who have ever taken the drugs to be recent stoppers. That makes weight maintenance a product category in its own right.
Circana's study also tracked what happens to former users' baskets. Some habits stick: purchases of produce, personal care and household plastics and storage kept growing after people stopped. Others reversed, with beverages, refrigerated foods and frozen foods bouncing back. Cost was the main reason people stopped, and half of former users said they were likely to go back on the drugs.
At list prices, cost as the main exit reason is no mystery. As of 2026, without insurance, Wegovy runs roughly $1,300 to $1,400 a month and Zepbound roughly $1,100 to $1,200, according to the Halo-RX Meds explainer, which cites GoodRx; many plans cover the drugs for diabetes but not obesity. Stopping carries a physical cost too. In the STEP-4 trial the explainer cites, patients who stopped semaglutide regained a significant share of the weight they had lost within a year, which is the problem Kline's maintenance category would address.
Taken together, this indicates that many shoppers cycle between taking the drug, stopping and eating the halo way without it. The SupplySide session already split its breakouts along those lines: consumers on a GLP-1, those coming off one and those looking for alternatives. Kaufmann's advice to that room was to look at the consumer journey, understand the problems this population is trying to address and then use science to solve for them. For brands with frozen or beverage lines, the post-drug rebound in Circana's data matters most.
The figure to watch in Kline's next update is the 89 million. If pill formats and employer coverage push usage up quickly in Europe and Asia Pacific, the halo there will shrink relative to users. Those regions would then look more like the US, where planning for medicated users directly makes sense.
Sources
- How wide is the GLP-1 halo? ↗
- The GLP-1 Ripple Effect: How Weight Loss Medications ... ↗ · Food Industry Executive
- Top 3 education sessions from SupplySide Global ↗ · SupplySide Food & Beverage Journal
- Circana: GLP-1 Users to Represent 35% of U.S. Food and ... ↗ · Food Engineering
- GLP-1 Drugs: An Opportunity Rather Than a Threat | Food ... ↗ · Food Processing
Your experts belong here
Every story in MarketScale Food & Beverage starts with a company putting its plant managers, quality leads, and R&D teams on the record. Buyers are already reading this topic. The only question is whose experts they find.
Processors and grocery buyers vet suppliers hard, and your operations people are the ones who can satisfy them.
About the author
The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.